Cell Reports Medicine (Oct 2020)
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
- Jérémie Prévost,
- Romain Gasser,
- Guillaume Beaudoin-Bussières,
- Jonathan Richard,
- Ralf Duerr,
- Annemarie Laumaea,
- Sai Priya Anand,
- Guillaume Goyette,
- Mehdi Benlarbi,
- Shilei Ding,
- Halima Medjahed,
- Antoine Lewin,
- Josée Perreault,
- Tony Tremblay,
- Gabrielle Gendron-Lepage,
- Nicolas Gauthier,
- Marc Carrier,
- Diane Marcoux,
- Alain Piché,
- Myriam Lavoie,
- Alexandre Benoit,
- Vilayvong Loungnarath,
- Gino Brochu,
- Elie Haddad,
- Hannah D. Stacey,
- Matthew S. Miller,
- Marc Desforges,
- Pierre J. Talbot,
- Graham T. Gould Maule,
- Marceline Côté,
- Christian Therrien,
- Bouchra Serhir,
- Renée Bazin,
- Michel Roger,
- Andrés Finzi
Affiliations
- Jérémie Prévost
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
- Romain Gasser
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
- Guillaume Beaudoin-Bussières
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
- Jonathan Richard
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
- Ralf Duerr
- Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
- Annemarie Laumaea
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada
- Sai Priya Anand
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada
- Guillaume Goyette
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
- Mehdi Benlarbi
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
- Shilei Ding
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
- Halima Medjahed
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
- Antoine Lewin
- Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada
- Josée Perreault
- Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada
- Tony Tremblay
- Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada
- Gabrielle Gendron-Lepage
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
- Nicolas Gauthier
- Hôpital Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada
- Marc Carrier
- Hôpital Cité-de-la-Santé, Laval, QC H7M 3L9, Canada
- Diane Marcoux
- Hôtel-Dieu de Lévis, Lévis, QC G6V 3Z1, Canada
- Alain Piché
- Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5H4, Canada
- Myriam Lavoie
- CIUSSS du Saguenay-Lac-Saint-Jean, Hôpital de Chicoutimi, Chicoutimi, QC G7H 5H6, Canada
- Alexandre Benoit
- Hôpital de Verdun, Montreal, QC H4G 2A3, Canada
- Vilayvong Loungnarath
- CHU de Québec, Hôpital Enfant-Jésus, Quebec, QC G1J 1Z4, Canada
- Gino Brochu
- CIUSSS de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, QC G9A 5C5, Canada
- Elie Haddad
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; CHU Ste-Justine, Montreal, QC H3T 1C5, Canada; Département de Pédiatrie, Université de Montréal, Montreal, QC H3T 1C5, Canada
- Hannah D. Stacey
- Micheal G. DeGroote Institute for Infectious Disease Research, Master Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada
- Matthew S. Miller
- Micheal G. DeGroote Institute for Infectious Disease Research, Master Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada
- Marc Desforges
- INRS-Institut Armand Frappier, Laval, QC H7V 1B7, Canada; CHU Ste-Justine, Montreal, QC H3T 1C5, Canada
- Pierre J. Talbot
- INRS-Institut Armand Frappier, Laval, QC H7V 1B7, Canada
- Graham T. Gould Maule
- Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Marceline Côté
- Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Christian Therrien
- Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada
- Bouchra Serhir
- Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada
- Renée Bazin
- Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada
- Michel Roger
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada
- Andrés Finzi
- Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada; Corresponding author
- Journal volume & issue
-
Vol. 1,
no. 7
p. 100126
Abstract
Summary: SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
